In Suzhou, China on February 26, 2026, it was revealed that Intravesical Bacillus Calmette-Guérin (BCG) is the recommended treatment for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) individuals. The shortage of BCG products has emerged as a worldwide issue, affecting the availability of this essential therapy. This scarcity, along with the potential side effects associated with BCG treatment, has become a significant concern for healthcare providers and patients worldwide.